×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:TYME

Tyme Technologies Stock Forecast, Price & News

$0.27
-0.01 (-3.57%)
(As of 07/1/2022 03:59 PM ET)
Add
Compare
Today's Range
$0.26
$0.29
50-Day Range
$0.23
$0.35
52-Week Range
$0.22
$2.02
Volume
20,683 shs
Average Volume
740,827 shs
Market Capitalization
$46.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Tyme Technologies MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
3.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.42mentions of Tyme Technologies in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$225,068 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.89 out of 5 stars

Medical Sector

1127th out of 1,428 stocks

Pharmaceutical Preparations Industry

553rd out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive TYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyme Technologies and its competitors with MarketBeat's FREE daily newsletter.

Tyme Technologies logo

About Tyme Technologies (NASDAQ:TYME) Stock

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.

TYME Stock News Headlines

The Safest Way To Start Trading Is Here!
One look at Wall Street right now and anyone can tell: it’s a mess! But new trades can get an edge with “Options Trading Made Easy” by trading champion Chuck Hughes, the best guide to options trading in the modern market. Start with a small investment today and see where you can go! Get your copy now!
A Short History of the American Lawn
The Safest Way To Start Trading Is Here!
One look at Wall Street right now and anyone can tell: it’s a mess! But new trades can get an edge with “Options Trading Made Easy” by trading champion Chuck Hughes, the best guide to options trading in the modern market. Start with a small investment today and see where you can go! Get your copy now!
Tyme Technologies Non-GAAP EPS of -$0.13
TYME Technologies Reviews Potential Strategic Options
Tyme Technologies to Explore Strategic Options
Tyme Technologies, Inc. (TYME)
Tyme Shares Eyeball 52-Week Low
JinkoSolar, Tyme Technologies, Texas Instruments
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TYME
Fax
N/A
Employees
17
Year Founded
N/A

Company Calendar

Last Earnings
11/08/2021
Today
7/05/2022
Next Earnings (Estimated)
8/09/2022
Fiscal Year End
3/31/2023

Profitability

Net Income
$-23,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.47 per share

Miscellaneous

Free Float
143,104,000
Market Cap
$46.50 million
Optionable
Optionable
Beta
0.95














Tyme Technologies Frequently Asked Questions

How has Tyme Technologies' stock performed in 2022?

Tyme Technologies' stock was trading at $0.6031 at the beginning of the year. Since then, TYME shares have decreased by 55.2% and is now trading at $0.27.
View the best growth stocks for 2022 here
.

When is Tyme Technologies' next earnings date?

Tyme Technologies is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Tyme Technologies
.

How were Tyme Technologies' earnings last quarter?

Tyme Technologies, Inc. (NASDAQ:TYME) announced its quarterly earnings data on Monday, November, 8th. The company reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.03.
View Tyme Technologies' earnings history
.

Who are Tyme Technologies' key executives?

Tyme Technologies' management team includes the following people:
  • Mr. Richard Cunningham, CEO & Director (Age 51, Pay $355.97k)
  • Mr. Steven E. Hoffman, Co-Founder & Director (Age 59, Pay $819.66k) (LinkedIn Profile)
  • Mr. James Biehl J.D., Chief Legal Officer & Sec. (Age 58, Pay $645.52k)
  • Dr. Jonathan M. Eckard, Chief Bus. Officer (Age 48, Pay $556.56k)
  • Mr. Frank L. Porfido, Chief Financial Officer (Age 58)
  • Dr. Jan Marie-Albert Van Tornout M.D., M.Sc., Acting Chief Medical Officer (Age 66)

What other stocks do shareholders of Tyme Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Allena Pharmaceuticals (ALNA), OpGen (OPGN), Selecta Biosciences (SELB), MEI Pharma (MEIP), Pfizer (PFE) and SCYNEXIS (SCYX).

What is Tyme Technologies' stock symbol?

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

How do I buy shares of Tyme Technologies?

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tyme Technologies' stock price today?

One share of TYME stock can currently be purchased for approximately $0.27.

How much money does Tyme Technologies make?

Tyme Technologies (NASDAQ:TYME) has a market capitalization of $46.50 million. The company earns $-23,630,000.00 in net income (profit) each year or ($0.13) on an earnings per share basis.

How many employees does Tyme Technologies have?

Tyme Technologies employs 17 workers across the globe.

How can I contact Tyme Technologies?

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The official website for Tyme Technologies is www.tymeinc.com. The company can be reached via phone at (212) 461-2315 or via email at investorrelations@tymeinc.com.

This page (NASDAQ:TYME) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.